Journal of Dermatology最新文献

{"title":"Association of Comorbid Trauma and Stressor-Related Disorders in Pemphigus and Pemphigoid: A Case-Control Study","authors":"Isabella J. Tan, Gaurav N. Pathak, Suraj S. Pathak, Babar K. Rao, Mohammad Jafferany","doi":"10.1111/1346-8138.70260","DOIUrl":"10.1111/1346-8138.70260","url":null,"abstract":"<p>Autoimmune blistering diseases (AIBDs) such as pemphigus and bullous pemphigoid (BP) are chronic, debilitating disorders characterized by loss of keratinocyte adhesion. Pemphigus affects 0.5–3 per million annually, while BP, the most common AIBD, occurs in up to 50 per million, particularly in older adults [<span>1</span>]. The unpredictable relapses, prolonged immunosuppression, and disfiguring lesions contribute to substantial psychosocial burden. We evaluated the association between trauma- and stressor-related disorders and AIBDs using the All of Us (AoU) database.</p><p>A nested case–control study was conducted utilizing the AoU controlled tier data set version 8, and all cases of pemphigus and pemphigoid were included (concept IDs 135338 and 139899 respectively). Cases were matched to controls by age, race, and sex at birth (approximately 1:5 ratio) using nearest-neighbor propensity matching. Comorbid acute stress disorder (ASD; < 1 month), post-traumatic stress disorder (PTSD; ≥ 1 month), and generalized anxiety disorder (GAD; ≥ 6 months) were assessed. For each patient, GAD, PTSD, and ASD were evaluated once, based on the presence of a diagnosis code recorded after the initial AIBD diagnosis; multiple visits or repeated codes were not used to assess longitudinal changes. Group characteristics were compared using <i>χ</i><sup>2</sup> (or Fisher's) tests, and odds ratios (OR) with 95% confidence intervals (CI) were calculated.</p><p>The cohort included 165 pemphigus vulgaris and 250 BP patients matched to 823 and 1248 controls, respectively. Among pemphigoid patients, 144 had BP, 66 mucous membrane pemphigoid, and 40 unspecified pemphigoid. The majority of pemphigus patients were > 65 years of age (61.21%), White (61.82%), and female (58.79%). Similarly, most BP patients were > 65 years of age (67.60%), White (65.20%), and female (58.00%) (Table S1). In this cohort, comorbid GAD was not significantly increased in pemphigus (OR 1.03, 95% CI 0.56–1.88, <i>p</i> = 0.928) or pemphigoid (OR 0.52, 95% CI 0.26–1.01, <i>p</i> = 0.052) compared with matched controls. By contrast, both pemphigus and pemphigoid were associated with higher odds of comorbid ASD (pemphigus: OR 2.09, 95% CI 1.02–4.30, <i>p</i> = 0.045; pemphigoid: OR 2.57, 95% CI 1.30–5.08, <i>p</i> < 0.0065). Odds of comorbid PTSD were not increased in either pemphigus (OR 0.49, 95% CI 0.17–1.38, <i>p</i> = 0.176) or pemphigoid (OR 0.73, 95% CI 0.33–1.64, <i>p</i> = 0.453) (Table 1). In a subgroup analysis controlling for H02-class immunosuppressants, including systemic corticosteroids (Table S2), the association with comorbid ASD was not statistically significant, while comorbid GAD was lower in pemphigoid patients compared with controls (OR 0.38, 95% CI 0.20–0.73, <i>p</i> = 0.004), suggesting that immunosuppressant use, including systemic corticosteroids, may attenuate the observed association with psychiatric comorbidities.</p><p>Psychiatric comorbidities, particularly","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 6","pages":"961-962"},"PeriodicalIF":2.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1346-8138.70260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147625274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Japanese Spotted Fever With Marked Serological Cross-Reactivity to Rickettsia typhi Confirmed by Sequence-Based Molecular Analysis: A Case Report","authors":"Natsumi Fushida,&nbsp;Yasuhito Hamaguchi,&nbsp;Akihiko Hodatsu,&nbsp;Rie Koshida,&nbsp;Yuki Hashimoto,&nbsp;Motohiko Ogawa,&nbsp;Takashi Matsushita","doi":"10.1111/1346-8138.70265","DOIUrl":"10.1111/1346-8138.70265","url":null,"abstract":"<div>\u0000 \u0000 <p>We report a case of Japanese spotted fever (JSF) showing marked serological cross-reactivity with <i>Rickettsia typhi</i>, which made serological differentiation difficult. An 80-year-old man presented with fever and disseminated erythematous macules. Laboratory finding suggested a rickettsial infection. Minocycline treatment led to clinical improvement. Real-time polymerase chain reaction screening was positive for spotted fever group rickettsiae. Serological testing using paired sera demonstrated comparable increases in antibody titers against <i>R. japonica</i> and <i>R. typhi</i> in the convalescent phase, precluding differentiation based on serology alone. Sequence-based molecular analysis using DNA extracted from the patient's serum revealed 100% identity with <i>R. japonica</i> strain YH, leading to a definitive diagnosis of JSF. This case highlights the diagnostic challenges posed by serological cross-reactivity and underscores the clinical value of molecular diagnostic approaches when serological findings are inconclusive.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 6","pages":"956-960"},"PeriodicalIF":2.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147635157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nemolizumab for Lichen Amyloidosis With Serial Serum Interleukin-31 Levels: A Case Report","authors":"Tsuyoshi Inoue,&nbsp;Wakako Yoshioka,&nbsp;Daisuke Watabe,&nbsp;Hiroo Amano","doi":"10.1111/1346-8138.70263","DOIUrl":"10.1111/1346-8138.70263","url":null,"abstract":"<div>\u0000 \u0000 <p>Lichen amyloidosis (LA) is a chronic, intensely itchy skin disease that is often difficult to control with conventional therapies. Interleukin-31 (IL-31) is an itch-driving cytokine, and nemolizumab, an antibody to the IL-31 receptor, has become available for some pruritic dermatoses. We report a man in his 60s with a 6-year history of treatment-refractory LA on the trunk and extremities. He received nemolizumab 60 mg subcutaneously every 4 weeks because of persistent severe itch despite topical therapy. Itch intensity improved from 5/10 at baseline to 2/10 at Week 4 and to 1/10 at Week 8, remaining low thereafter. The papular lesions showed marked flattening and regression after five doses, leaving only faint residual pigmentation. Serum IL-31 concentrations were measured immediately before each injection using a commercial assay. Values decreased after Week 4, reached the lowest level by Week 12 during near-complete remission, and showed a mild increase by Week 16 without clinical relapse. This case suggests that blocking IL-31 signaling can rapidly and durably improve severe LA and that repeated serum IL-31 measurements may help support treatment response over time.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 6","pages":"948-951"},"PeriodicalIF":2.7,"publicationDate":"2026-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147655593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of Medical Costs of Melanoma Using a Japanese National Database","authors":"Meiko Goto,&nbsp;Hiroyuki Goto,&nbsp;Tsubasa Bito,&nbsp;Ryota Kawai,&nbsp;Sho Hiroyasu,&nbsp;Ayumi Shintani,&nbsp;Daisuke Tsuruta","doi":"10.1111/1346-8138.70227","DOIUrl":"10.1111/1346-8138.70227","url":null,"abstract":"<div>\u0000 \u0000 <p>The advent of immune checkpoint inhibitors (ICIs) and targeted therapeutic agents (TTAs) has improved melanoma treatment. With the ongoing development of novel drugs, treatment options are expected to expand further. However, this is also anticipated to increase the financial burden on patients. Changes in medical costs for melanoma patients have not yet been examined in Japan. Therefore, we herein conducted a retrospective observational study using data from a Japanese nationwide database. The dataset comprised 14 727 patients diagnosed with melanoma between April 2008 and June 2023. The mean monthly cost per patient was calculated and changes were evaluated. The results obtained showed that the mean monthly cost per patient has consistently increased, and a breakdown revealed that drug costs for ICIs and TTAs accounted for a significant percentage of these costs. Furthermore, the usage rates of ICIs and TTAs have steadily increased since their approval in 2014, with a notable rise being observed in 2018 when adjuvant therapies were approved in Japan. An interrupted time series analysis further confirmed a significant increase in medical costs around 2018. While ICIs and TTAs represent major advances in melanoma treatment, their increasing use underscores the need for a careful evaluation of both clinical benefits and economic sustainability.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"818-823"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Macrophages in Pigmentary Disorders","authors":"Huiyi Yao,&nbsp;Xingyue Gao,&nbsp;Wenzhong Xiang","doi":"10.1111/1346-8138.70065","DOIUrl":"10.1111/1346-8138.70065","url":null,"abstract":"<div>\u0000 \u0000 <p>Diseases associated with skin pigmentation include hyperpigmentation and hypopigmentation. Macrophages are involved in melanogenesis and the development of skin pigmentary disorders, and they affect the production and distribution of melanin mainly through phagocytosis and secretion. They can either phagocytose melanin and deposit it in the dermis or secrete a variety of cytokines like interferon (IFN)-<i>γ</i>, tumor necrosis factor (TNF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and some interleukins (ILs) such as IL-1, IL-6, IL-8, and IL-18. The interaction between macrophages and other cells is responsible for the secretion of these cytokines. Macrophages can also promote pigmentation in hyperpigmentation disorders, such as post-inflammatory hyperpigmentation (PIH), drug-induced pigmentation (DIP), senile lentigo (SL), and melasma, as well as hypopigmentation disorders such as vitiligo and halo nevus (HN). In this review, we summarize the role of macrophages in the development of pigmentary diseases and provide new insights for the identification of potential targets for pigmentary diseases.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"719-732"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145566842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Washcloth Withdrawal and Pruritus: A Single-Center Retrospective Observational Study","authors":"Hajime Miyazawa,&nbsp;Ken Natsuga,&nbsp;Takashi Seo,&nbsp;Hideyuki Ujiie","doi":"10.1111/1346-8138.70177","DOIUrl":"10.1111/1346-8138.70177","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic pruritus is common and often difficult to treat. Although several studies have examined how cleansing agents used during bathing relate to pruritus, the effect of washcloth use during bathing, including whether discontinuation is associated with lower itch, remains unclear. We conducted a single-center retrospective observational study of 79 washcloth users with diverse skin diseases to evaluate pruritus before and after washcloth withdrawal without treatment escalation. Pruritus severity was measured using a 0 to 10 Numerical Rating Scale (NRS), and scores were compared within patients. At baseline, the mean NRS score among users was 4.79, with cotton and synthetic-fiber washcloths showing comparable scores. Among those who discontinued washcloth use without treatment escalation, mean NRS scores decreased from 4.89 to 1.90 (<i>p</i> &lt; 0.0001), while those who continued showed no significant change in pruritus scores (from 3.86 to 3.60; <i>p</i> &gt; 0.9999). Our data suggest that discontinuing washcloth use may be associated with lower pruritus scores and could represent a practical, low-cost, and none-invasive measure for pruritus management warranting prospective evaluation.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"774-779"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145550","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Seventy-Two-Week Real-World Outcomes of Tralokinumab Treatment for Moderate-To-Severe Atopic Dermatitis: Analyses Stratified by Baseline Rash and Itch Severity","authors":"Manami Yoneyama,&nbsp;Teppei Hagino,&nbsp;Akihiko Uchiyama,&nbsp;Hidehisa Saeki,&nbsp;Eita Fujimoto,&nbsp;Sei-ichiro Motegi,&nbsp;Naoko Kanda","doi":"10.1111/1346-8138.70187","DOIUrl":"10.1111/1346-8138.70187","url":null,"abstract":"<div>\u0000 \u0000 <p>An anti–interleukin-13 antibody tralokinumab is effective for atopic dermatitis (AD). However, there are no real-world studies on its long-term outcomes in patients stratified by rash and itch severity. To evaluate the effectiveness of 72-week tralokinumab treatment in 4 groups of AD patients, stratified by baseline investigator's global assessment (IGA) and peak pruritus numerical rating scale (PP-NRS), we conducted a prospective study of 167 Japanese patients with moderate-to-severe AD from October 2023 to October 2025. Patients received tralokinumab every two weeks. Eczema area and severity index (EASI), IGA, and PP-NRS were assessed at weeks 0, 4, 12, 16, 24, 36, 48, 60, and 72. Data were analyzed separately in 4 groups; IGA 3/PP-NRS &lt; 7, IGA 3/PP-NRS ≥ 7, IGA 4/PP-NRS &lt; 7, and IGA 4/PP-NRS ≥ 7. Mean EASI and PP-NRS decreased in all groups through week 72. The rates achieving IGA 0/1, EASI 100, and PP-NRS ≥ 4-point reduction were highest in the group with IGA 3/PP-NRS ≥ 7 (53.6%, 17.9%, and 92.0%) while lowest in that with IGA 4/PP-NRS &lt; 7 (10.0%, 0%, and 22.2%). Tralokinumab improved rash and itch throughout 72 weeks across all groups stratified by rash and itch severity.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"789-796"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146204567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Erythroderma-Like Manifestations and High Fever in Palisaded Neutrophilic and Granulomatous Dermatitis Without Any Underlying Systemic Immunological Disease","authors":"Tomoko Yamate,&nbsp;Mizuki Goto,&nbsp;Haruto Nishida,&nbsp;Takashi Anan,&nbsp;Yutaka Hatano","doi":"10.1111/1346-8138.70207","DOIUrl":"10.1111/1346-8138.70207","url":null,"abstract":"<div>\u0000 \u0000 <p>Palisaded neutrophilic and granulomatous dermatitis (PNGD) is a reactive granulomatous dermatitis; the umbrella term includes interstitial granulomatous dermatitis and interstitial granulomatous drug reaction, in addition to PNGD. The histological findings of PNGD include leukocytoclastic vasculitis, neutrophilic infiltrates, and collagen degeneration with palisades of histiocytes and small granulomas. Clinically, the patients show symmetrical, smooth papules that are skin-colored to red, some with central umbilication or crusting, located mainly on the elbows and extremities. PNGD usually occurs with some systemic diseases, such as systemic lupus erythematosus, suggesting a cutaneous reaction pattern due to underlying internal inflammation. Although the present case was histologically diagnosed as PNGD, while excluding other granulomatous diseases, multiple indurated erythematous papules with a tendency to coalesce widely were seen, mimicking erythroderma without any underlying immunological diseases. In addition, the eruption coincided with fluctuating high fever. This was a rare case of PNGD with no underlying immunological disease that presented with severe manifestations such as fever and erythroderma.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"841-844"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147380382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Healthcare Resource Utilization and Use of Biologics in Chronic Spontaneous Urticaria","authors":"Lillian D. Sun,&nbsp;Ajay Behl,&nbsp;Peter N. Danilov,&nbsp;Fatai Y. Agiri,&nbsp;Kathryn M. Pridgen,&nbsp;Amanda Christine F. Esquivel,&nbsp;Julie A. Lynch,&nbsp;Elma Baron","doi":"10.1111/1346-8138.70234","DOIUrl":"10.1111/1346-8138.70234","url":null,"abstract":"<p>Biologic therapies have emerged as effective treatments for chronic spontaneous urticaria (CSU), a debilitating skin disease. However, real-world data on their use are limited. This retrospective descriptive study analyzes the time from diagnosis to biologic therapy initiation and the CSU-specific healthcare resource utilization (HCRU) among patients with ≥ 2 urticaria diagnoses or one urticaria and one angioedema diagnosis with no diagnosis of urticarial vasculitis. This study uses data from the Veterans Health Administration from January 2011 through December 2021. We measured time from diagnosis to biologic initiation and CSU-specific HCRU (outpatient visits, inpatient admissions, emergency room visits, and pharmacy claims) in the 12 month pre- and post-index periods. The final cohort included 26 387 Veterans with CSU. In the 12 month post-index period, 23 699 Veterans (89.8%) started treatment, but only 613 Veterans (2.6%) started biologic therapy, with a median initiation time of 337 days. CSU-specific HCRU increased in the post-index period across all categories. 66.8% of Veterans had pharmacy claims pre-index date compared to 89.8% post-index date, and 92.4% of Veterans had outpatient visits pre-index date compared to 96.7% post-index date. The findings suggest that initiation of biologics may be considered sooner in appropriate patients. The increased HCRU observed in the post-index period highlights the burden that CSU places on patients and the healthcare system.</p>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"832-836"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13150668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147617320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin","authors":"Thalita Bastos,&nbsp;Makoto Ito,&nbsp;Masahiro Kamata,&nbsp;Teruo Shimizu,&nbsp;Hideaki Uchida,&nbsp;Yoshiki Okada,&nbsp;Ayu Watanabe,&nbsp;Yayoi Tomura,&nbsp;Ryosuke Takeshima,&nbsp;Azusa Hiura,&nbsp;Kotaro Hayashi,&nbsp;Atsuko Fukuyasu,&nbsp;Takamitsu Tanaka,&nbsp;Takeko Ishikawa,&nbsp;Yayoi Tada","doi":"10.1111/1346-8138.70209","DOIUrl":"10.1111/1346-8138.70209","url":null,"abstract":"<div>\u0000 \u0000 <p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder characterized by pruritus, barrier dysfunction, and complex immune dysregulation. Phototherapy with narrow-band ultraviolet B (NB-UVB) or 308 nm excimer devices is clinically effective for AD, but the underlying mechanisms remain incompletely understood. In this study, we investigated the therapeutic effects of a 308-nm excimer lamp using a murine model of AD induced by topical application of the vitamin D3 analog MC903. C57BL/6 mice were treated with MC903 for 13 consecutive days, with or without irradiation by a 308-nm excimer lamp at 100 mJ/cm² every other day. Clinical severity was assessed daily, and histological, immunohistochemical, and molecular analyses were performed on lesional skin. Excimer irradiation significantly alleviated MC903-induced dermatitis from days 4 to 12, with reduced clinical severity scores, epidermal thickness, and acanthosis compared with non-irradiated controls. Immunohistochemical analysis revealed a significant decrease in intraepidermal PGP9.5-positive nerve fibers in irradiated mice, suggesting that excimer therapy attenuates pruritus through neuroimmune modulation. Furthermore, excimer irradiation increased dermal infiltration of Foxp3-positive regulatory T cells and decreased plasma IgE levels, although no significant upregulation of IL-10 mRNA was detected. Importantly, quantitative PCR demonstrated that excimer irradiation reduced thymic stromal lymphopoietin (TSLP) expression in lesional skin, while levels of other Th2-related cytokines such as IL-4 and IL-13 remained unchanged. These findings indicate that 308-nm excimer lamp therapy ameliorates AD-like dermatitis through dual mechanisms: suppression of intraepidermal nerve fibers and downregulation of epithelial-derived TSLP, together with enhanced regulatory T-cell infiltration. This study provides new mechanistic insights into the immunological and neurocutaneous effects of excimer phototherapy, supporting its clinical use in AD and potentially other inflammatory skin diseases.</p>\u0000 </div>","PeriodicalId":54848,"journal":{"name":"Journal of Dermatology","volume":"53 5","pages":"810-817"},"PeriodicalIF":2.7,"publicationDate":"2026-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147373806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}